A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin

Diabetes Care

Volumn 26, Issue 1, 2003, Pages 125-131

  McNulty, Steven J ^a   Ur, Ehud ^b   Williams, Gareth ^a  

^a University Hospital Aintree ^*  (United Kingdom)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LIPID; METFORMIN; PLACEBO; SIBUTRAMINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HEMOGLOBIN DETERMINATION; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

APPETITE DEPRESSANTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CYCLOBUTANES; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; METFORMIN; MIDDLE AGED; OBESITY; TREATMENT OUTCOME;

EID: 0038510366     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.1.125     Document Type: Article

References (27)

1. Colditz G, Willet W, Rotnitzk A, Manson JE: Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 122:481-486, 1995
2. Lew EA, Garfinkel L: Variations in mortality by weight among 750,000 men and women. J Chronic Dis 32:563-576, 1979
3. Peiris AN, Struve MF, Mueller RA, Lee MB, Kissebah AH: Glucose metabolism in obesity: influence of body fat distribution. J CIin Endocrinol Metab 67:760-767, 1988
4. Garner DM, Wooley SC: Confronting the failure of behavioural and dietary treatments for obesity. Clin Psychol Rev 11:729-780, 1991
5. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, Hennekens CH, Speizer FE: Body weight and mortality among women. N Engl J Med 333:677-685, 1995
6. SIGN (Scottish Intercollegiate Guidelines Network): Obesity in Scotland: Integrating Prevention With Weight Management. Edinburgh, U.K., HMSO, 1996
7. Wing RR, Shoemaker M, Marcus MDM, McDermott M, Gooding W: Variables associated with weight loss and improvements in glycemic control in type 2 diabetic patients. Arch Intern Med 147:1749-1753, 1990
8. Goldstein DJ: Beneficial health effects of modest weight loss. Int J Obes 16:397-415, 1992
9. Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet, sulphonylureas, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirements for multiple therapies (UKPDS 49): UK Prospective Diabetes Study (UKPDS) Group. JAMA 21:2005-2012, 1999
10. Scheen AJM, Paolisso G, Salvatore T, Lefèbvre PJ: Improvement of insulin-induced glucose disposal in obese patients with NIDDM after one week treatment of D-fenfluramine. Diabetes Care 14:325-332, 1991
11. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J: Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care 21:1288-1294, 1998
12. Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC: Sibutramine: a novel anti-obesity drug: a review of the pharmacological evidence to differentiate it from D-amphetamine and D-fenfluramine. Int J Obes 22:S18-S29, 1998
13. Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, Weinstein SP: Weight loss with sibutramine improves glycemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2:175-187, 2000
14. Han TS, van Leer EM, Seidell JC, Lean MEJ: Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. BMJ 311:1401-1405, 1995
15. Nagi DK, Yudkin JS: Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 16:621-628, 1993
16. Lean MEJ, Powrie JK, Anderson AS, Garthwaite PH: Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 7:228-233, 1990
17. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
18. Lee IM, Paffenbarger RS: Changes in body weight and longevity. JAMA 268:2045-2049, 1992
19. Wing RR: Improving dietary adherence in patients with diabetes. In Nutrition and Diabetes. Jovanovic L, Peterson CM, Eds. New York, Alan R. Liss, 1995, p. 161-186
20. Balfour JA, Plosker GL: Rosiglitazone. Drugs 57:921-930, 1999
21. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WH, Van Gaal LF, for the STORM study group: Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 356:2119-2125, 2000
22. Poirier P, Després J-P: Lipid disorders in diabetes mellitus. In Textbook of Diabetes. 3rd ed. Pickup J, Williams G, Eds. Oxford, U.K., Blackwell Science, 2002, p. 54.1-54.29
23. UK Prospective Diabetes Study Group: Tight blood pressure and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713, 1998
24. Lehmann ED, Gosling RG, Sönksen PH: Arterial wall compliance in diabetes. Diabet Med 9:114-119, 1992
25. Anderson KM, Wilson PW, Odell PM, Kannel WB: An updated coronary risk profile: a statement for health professionals. Circulation 83:356-362, 1991
26. Assmann G, Culler P, Schülte H: The Munster heart study (PROCAM): results of follow-up at 8 years. Eur Heart J 19 (Suppl. A):A2-A11, 1998
27. Palatini P: Elevated heart rate as a predictor of increased cardiovascular morbidity. J Hypertens 17 (Suppl. 3)S3-S10, 1999